Arcus Biosciences

Biotech & Life Sciences · Hayward, United States · Founded 2015 · IPO 2018

Exciting young company founded on a vision of creating new cancer therapeutics through the utilization of emerging insights in immunology MoreLess

Arcus Biosciences is a biopharmaceutical company dedicated to developing innovative combination therapies to combat cancer. The company focuses on designing and advancing medicines that improve the lives of cancer patients. Arcus operates in the oncology market, primarily serving patients, healthcare providers, and research institutions. The business model revolves around conducting clinical trials to test the efficacy and safety of their drug candidates, which are then brought to market upon successful approval. Revenue is generated through partnerships, licensing agreements, and eventual sales of approved therapies. Arcus is committed to relentless research and development, leveraging cutting-edge science to create potential cures for cancer.

Keywords: oncology, biopharmaceutical, combination therapies, cancer research, clinical trials, drug development, innovative medicines, healthcare, biotechnology, immunotherapy.

Valuation $2.84B

Revenue $247M

Total funding $100–500M

Power Law Unicorn$1–10B valuation tier Thoroughbred$100M+ revenue

Talent graph

Arcus Biosciences's talent

Book a demo to see the people

Employees mapped 646 incl. 2 AI specialists

Founders /100 quality score

Key operators 15 quality /100

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Investors

15 investors on Arcus Biosciences's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 9 investors entered at this stage

The Column Group

Celgene

Invus

Novartis

Taiho Pharma

Foresite Capital

RTA Capital

SVB Leerink

Series B+ 6 investors entered at this stage

Wellington Management

Aisling Capital

Decheng Capital

EcoR1 Capital

Gilead Sciences

Hercules Capital

Global footprint

Where Arcus Biosciences has talent and traffic

Workforce by country

9 countries with
team presence

🇺🇸 United States98%

🇰🇷 South Korea0.4%

🇧🇷 Brazil0.2%

🇫🇷 France0.2%

🇵🇭 Philippines0.2%

Top 5 of 9 shown

Web traffic by country

16K monthly visits
across markets

🇺🇸 United States81.9%

🇮🇳 India15.6%

🇧🇪 Belgium1.3%

Top 3 markets shown

Patent intelligence

$80M patent portfolio · 63 active families

Estimated portfolio value

$80M

2.8% of market cap · comparable to top peer Dicerna Pharmaceuticals ($100M)

63 active patent families

Where Arcus Biosciences innovates BiochemistryCancer researchCarcinosisCombinatorial chemistryDisease

Where Arcus Biosciences concentrates vs peers

Each axis is a top-10 topic across Arcus Biosciences and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Arcus Biosciences

An AI-synthesized read of the highest-engagement posts about Arcus Biosciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Arcus Biosciences on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles